_1555390422229.png?format=webp&height=120&width=120){kind=logo}
About Efung Capital
Efung Capital is a venture capital firm founded in 1996. It is primarily based out of Shenzhen, China. As of Dec 2021, Efung Capital has invested in 4 companies. It primarily invests in Series B round in China based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and High Tech. Most recently it participated in the $***** Seed round of Ringcode Bio Overall, Efung Capital portfolio has seen 1 IPO, namely Insight Lifetech. A lot of funds co-invest with Efung Capital, with names like SDIC sharing a substantial percentage of its portfolio. Efung Capital has team of 4 people including 3 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Seed & 1 more
Portfolio IPOs
Portfolio Soonicorns
Efung Capital's List of All Investments
Efung Capital has a portfolio of 4 companies. Their most notable investmentis in GeneScience PharmaceuticalsTheir portfolio spans across China and United States. They have invested in Life Sciences, HealthTech, High Tech, across Series B, Seed and 1 more. Here is the list of all investments by Efung Capital:
Insight Lifetech is developing medical devices for precision diagnosis of coronary diseases. Its device, TruePhysioTM Microcatheter provides hemodynamic information for the diagnosis and treatment of coronary and peripheral artery diseases. The device is an application in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve (FFR).
Key facts about Insight Lifetech
- Founded Year: 2015
- Location: Shenzhen (China)
- Stage: Public
- Total Funding till date: $42.7M
- Employee Count: 48 as on Sep 30, 2026
- Investors: Decheng Capital, Qiming Venture Partners and 9 Others
- Latest Funding Round: Series C, Dec 31, 2020, $*****
- Highlight: Public
_1531899939020.png?format=webp&height=120&width=120){kind=logo}
Provides genetically engineered pharmaceutical products. They use the technology of genetic engineering and recombinant technology to produce their several propriety like GenLei Jintropin (human growth hormone), Genfulin (rDNA origin), recombinant human granulocyte-macrophage stimulating factor gel for burn treatment, and octreotide acetate for child growth.
Key facts about GeneScience Pharmaceuticals
- Founded Year: 1996
- Location: Changchun (China)
- Stage: Series B
- Employee Count: 8 as on Sep 30, 2026
- Investors: Haitong Bank, China Huarong Asset Management and 3 Others
- Latest Funding Round: Series B, Mar 04, 2021, $*****
- Highlight: Editors' Pick
3. Ringcode Bio
Developer of a circular RNA technology platform for therapeutics. It offers infectious disease vaccines, personalized tumor vaccines, protein replacement therapy, and immunotherapy based on a circular RNA system.
Key facts about Ringcode Bio
- Founded Year: 2021
- Location: Shanghai (China)
- Stage: Seed
- Total Funding till date: $20M
- Investors: K2VC, Efung Capital and 2 Others
- Latest Funding Round: Seed, Dec 16, 2021, $*****
- Highlight: Editors' Pick
Innovative cancer immunotherapy company developing next-generation adoptive T cell therapies. They are focused on engineering immune cells for potent cancer treatment, specifically targeting cancer in a specific, efficient, and durable manner. Their approach utilizes a unique class of CD4 T cells to enhance the anti-tumor function of CD8 T cells, directly targeting tumor cells. The platform harnesses the synergistic effects of CD8-TCRs and CD4-TCRs, and HSC derived T cells, to provide durable remission for cancer patients. This immuno-oncology company specializes in potent cancer immunotherapy using a dual T cell receptor approach, including genetic modification of patients’ mature T cells and reprograming patient derived hematopoietic stem cells (HSCs). This creates a continual, long-term source of cancer-fighting T cells, leading to sustained attack on cancer cells.
Key facts about Tactiva Therapeutics
- Founded Year: 2017
- Location: Buffalo (United States)
- Stage: Series A
- Total Funding till date: $35M
- Employee Count: 5 as on Sep 30, 2026
- Investors: VI Ventures, Panacea Venture and 1 Other
- Latest Funding Round: Series A, Dec 03, 2018, $*****
- Highlight: Editors' Pick
Efung Capital's Year-on-Year Investment Trends
Efung Capital has invested in 4 companies over the last 8 years, with an average of 0 new investment annually in the last 5 years. Its most recent first time investment was in Ringcode Bio.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 0 | 0 | 0 |
2024 | 0 | 0 | 0 |
2023 | 0 | 0 | 0 |
2022 | 0 | 0 | 0 |
2021 | 2 | 0 | 2 |
2020 | 1 | 0 | 1 |
2019 | 0 | 0 | 0 |
2018 | 1 | 0 | 1 |
Efung Capital's Investments by Stage
Efung Capital has made 2 investments in Series B stage with an average round size of $28.2M, 1 investment in Seed stage with an average round size of $20M and 1 investment in Series A stage with an average round size of $35M.Stage of entry | No. of Investments |
|---|---|
Series B | 2 |
Seed | 1 |
Series A | 1 |
Note: We have considered here, only first round of investments
Efung Capital's Investments by Sector
Efung Capital has a diverse portfolio, with companies operating in the Life Sciences, High Tech, HealthTech and Internet of Things - Industry Applications. Notably, it has invested in 4 Enterprise (B2B) companies and 4 Tech companies.Sector | No. of Investments |
|---|---|
Life Sciences | 4 |
High Tech | 3 |
HealthTech | 1 |
Internet of Things - Industry Applications | 1 |
Note: We have considered here, only first round of investments
Efung Capital's Investments by Geography
Efung Capital has made most investments in China (3), followed by United States where it has made 1 investment.Country | No. of Investments |
|---|---|
China | 3 |
United States | 1 |
Note: We have considered here, only first round of investments
Efung Capital's recent investments
Efung Capital has not made any investment in 2026 so far.Here are the most recent investments by Efung Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Dec 16, 2021 | China | Seed | 3557 | [+2] | |
Mar 04, 2021 | China | Series B | 1141 | [+1] | |
Apr 07, 2020 | China | Series B | 3650 | [+4] | |
Dec 03, 2018 | United States | Series A | 4851 | [+1] |
IPOs and Publicly Listed companies in Efung Capital's Portfolio
1 of Efung Capital's portfolio company became public - Insight Lifetech. It got listed on the Shanghai Stock Exchange (SSE), in Feb 2026.Here are Efung Capital's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Feb 05, 2026 | Apr 07, 2020 | Series B | 9828 |
Team profile of Efung Capital
Efung Capital has a team of 4 members including 3 Partners and 1 Principal located in China. Efung Capital's team does not sit on the board of any company as of now.Here is a list of all team members in Efung Capital:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Shenzhen | - | - | |
Partner | Shenzhen | - | - | |
Partner | China | - | - | |
Principal | Shenzhen | - | - |
Co-investors of Efung Capital
Over the past 8 years, 17 investors have co-invested in Efung Capital's portfolio companies. This includes only funds.
- Invested before Efung Capital: Sherpa Venture Capital and Sequoia Capital China have invested in rounds before Efung Capital. There is 1 company where Sherpa Venture Capital has invested before Efung Capital and 1 company where Sequoia Capital China has invested before Efung Capital.
- Top Co-investors of Efung Capital: 12 investors entered a company along with Efung Capital. These include investors like SDIC (1 company).
- Invested after Efung Capital: A total of 3 investors have invested in Efung Capital's portfolio after their investments. Top Investors include Qiming Venture Partners (1 company), TigerYeah Capital (1 company) and SDIC Chuanghe Fund Management (1 company).
Recent News related to Efung Capital
•
•
CellOrigin raises new funds to Jump-start iPSC immune cell therapy products toward clinicsBioSpectrum Asia•Mar 31, 2022•CellOrigin, Jifeng Ventures, Kunlun Capital, Ginkgo Valley Capital and 1 other
•
Atom Bioscience Raises $45 Million in Series C Round of Financing to Advance Development of Small Molecule Drugs for Inflammatory and Metabolic DiseasesBusiness Wire•Jan 05, 2022•New Element Medicine, ShenZhen GTJA Investment Group, Efung Capital, Oriza Holdings and 4 others
•
Chinese biopharma startup lands $123m funding in series A, B roundsTech in Asia•Mar 04, 2021•Genscience, IDG Capital, New Alliance Capital, Haitong Bank and 2 others
•
Investors throw over $140m to 3DMedGlobal Corporate Venturing•Oct 12, 2020•3DMed, Tigermed, Efung Capital, Header Capital
•
Chinese pharmaceutical technology company Asieris Pharmaceuticals completes hundreds of millions of yuan in Series C fundingVOLANEWS•Mar 24, 2020•Asieris, Shenzhen Guozhong Venture Capital Management, Efung Capital, E Fund Management and 1 other
•
Harbour BioMed Raises $75M in Series B+ Venture Capital FinancingFinSMEs•Mar 12, 2020•Harbour BioMed, SK, Efung Capital, ZSVC and 13 others
•
Elicio Therapeutics Completes $33 Million Series B FinancingCMOCRO•Oct 02, 2019•Elicio, Clal Biotechnology Industries, Livzon Pharmaceutical, Efung Capital
•
KBP Biosciences Raises $76 Million in Series A Financing and Appoints Brian P. McVeigh as Chief Executive OfficerBusiness Wire•Jan 05, 2018•KBP BioSciences, Advantech Capital, Sangel Capital, Ping An Ventures and 8 others
•
